)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Cellectar Biosciences
Cellectar Biosciences (CLRB) investor relations material
Cellectar Biosciences Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary4 Mar, 2026
Executive summary
Achieved significant regulatory and clinical progress in 2025, advancing iopofosine I 131 for Waldenstrom's macroglobulinemia toward EU Conditional Marketing Authorization submission and 2027 commercialization, while expanding the radiotherapeutic pipeline.
Initiated Phase 1b study for CLR 125 in triple-negative breast cancer, with early data expected by mid-2026.
Strengthened supply chain and expanded global intellectual property estate, securing new patents and commercial-scale isotope supply agreements.
Completed IND-enabling work for CLR 225, with phase 1 trial ready pending funding.
Raised $15.2 million, extending cash runway into Q3 2026 to support ongoing pipeline advancement.
Financial highlights
Ended 2025 with $13.2 million in cash and equivalents, down from $23.3 million at end of 2024.
Research and development expenses for 2025 were $11.5 million, down from $26.6 million in 2024, mainly due to reduced clinical activity and manufacturing costs.
General and administrative expenses fell to $11.5 million from $25.6 million year-over-year, reflecting reduced pre-commercialization efforts.
Net loss for 2025 was $21.8 million ($8.35 per share), improved from $44.6 million ($36.52 per share) in 2024.
Other income, net, was $1.2 million in 2025, compared to $7.3 million in 2024, primarily due to non-cash warrant valuation impacts.
Outlook and guidance
On track to submit EU conditional marketing authorization for iopofosine in Q3 2026, with potential approval and commercialization in 2027.
US NDA submission planned shortly after initiation of confirmatory Phase III trial, leveraging breakthrough therapy designation and accelerated approval pathway.
Early interim data for CLR 125 expected mid-2026; steady cadence of results anticipated throughout the year.
Cash runway expected to fund operations into Q3 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next Cellectar Biosciences earnings date
Q1 202612 May, 2026
Cellectar Biosciences
Next Cellectar Biosciences earnings date
Q1 202612 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Cellectar Biosciences Inc (CLRB) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer. Leveraging its proprietary phospholipid drug conjugate (PDC) delivery platform, Cellectar aims to develop targeted therapies designed to enhance treatment outcomes by selectively delivering cancer-killing agents to tumor cells, minimizing the impact on normal tissues. The company is headquartered in Florham Park, New Jersey, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage